Background: PAM50 (ProsignaV R ) identifies a gene-expression profile that categorises early breast cancer (BC) in intrinsic subtypes and gives prognostic estimation based on a 10 year-recurrence risk score (ROR). The purpose of this study was to evaluate the impact of PAM50's information on adjuvant treatment decisions. Methods: Prospective collection of BC cases treated in a Cancer Centre in the last 10 months, in which PAM50 was used to define treatment strategy. Demographic, clinic and pathologic characteristics are described. Concordance between immunohistochemistry (IHC) and PAM50 subtypes were assessed as well as therapeutic decision changes according to risk stratification, using blind revision. Categorical variables were compared used chi-square test. (40%)]. Based on PAM50, adjuvant strategy was changed in 28 patients (28%), (p ¼ 0.001): 15 (54%) changed from endocrine therapy (ET) only to chemotherapy (CT) also and 13 (46%) changed from CT and ET to ET only. Conclusions: PAM50 availability results in 28% change in adjuvant plan with more cases of chemotherapy. The 34% discordance with classic IHC subgroups, especially in luminal B tumours, underlines the need for more accurate tests in this heterogeneous population to define the adequate adjuvant strategy. A longer follow up is important to evaluate the prognostic value of clinical decisions based on genetic signatures. Legal entity responsible for the study: Breast Department -IPO-Porto. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Background: PAM50 (ProsignaV R ) identifies a gene-expression profile that categorises early breast cancer (BC) in intrinsic subtypes and gives prognostic estimation based on a 10 year-recurrence risk score (ROR). The purpose of this study was to evaluate the impact of PAM50's information on adjuvant treatment decisions. Methods: Prospective collection of BC cases treated in a Cancer Centre in the last 10 months, in which PAM50 was used to define treatment strategy. Demographic, clinic and pathologic characteristics are described. Concordance between immunohistochemistry (IHC) and PAM50 subtypes were assessed as well as therapeutic decision changes according to risk stratification, using blind revision. Categorical variables were compared used chi-square test. (HR ¼ 3, 49 [1, 58] ) were significant prognostic factors. There was no prognostic value of age<35 years, Ki 67 cut-off of 20% and nodal capsule rupture. There was a highly significant difference (p < 0.0001) in overall survival between the 4 intrinsic subtypes. Five-year overall survival was 95% for Luminal A, 90% for Luminal B, 56% for HER2 and 36% for basal-like. On multivariate analysis receptors expression and intrinsic subtype were significantly associated to survival (p < 0.05). Conclusions: In NPI aggressive disease, the most important prognostic factors were receptors expression and intrinsic subtype. The elaboration of a histology-matched NPI score could afford better prognostic evaluation of early stage breast cancer. Legal entity responsible for the study: Abderrahmen Mami Hospital, Medical Oncology Department. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
217P Subgroup analyses of efficacy from a phase III study comparing SB3
(trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients Biometrics, Samsung Bioepis, Suwon, Republic of Korea, 7 Medical Affairs, Samsung Bioepis, Suwon, Republic of Korea Background: SB3 has been approved by the European Commission as a biosimilar of reference trastuzumab (TRZ). Equivalence for efficacy between SB3 and TRZ based on breast pathologic complete response (bpCR) rates has been demonstrated and previously reported.
1 Here we report results of subgroup analyses of efficacy by baseline disease characteristics and demographics. Methods: Patients received either SB3 or TRZ for 8 cycles concurrently given with chemotherapy (docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide). Then patients underwent surgery followed by 10 cycles of SB3 or TRZ. The primary endpoint was bpCR rate. Subgroup analyses of bpCR rate, total pathologic complete response (tpCR) rate, and overall response rate (ORR) by region, age, ethnicity, hormone receptor status, breast cancer type, and menopausal status was performed. Results: 800 patients (SB3, n ¼ 402; TRZ, n ¼ 398) were included in the per-protocol set (PPS). The bpCR rates were 51.7% for SB3 and 42.0% for TRZ with adjusted difference of 10.70% (95% CI, 4.13, 17.26). Subgroup analysis results are provided in the table. A trend of favourable efficacy of SB3 compared to TRZ was maintained in most of subgroup analyses. Similar trends were observed in the subgroup analysis of tpCR rate and ORR. Table: bpCR rates by baseline demographics and disease characteristics. 
